生物制药公司Mirum Pharmaceuticals, Inc.（MIRM）今日盘后股价大涨9.20%，引发投资者关注。这一显著涨幅主要源于公司发布的最新季度财报数据大幅超出市场预期。
根据公司公布的财报，截至6月30日的季度，Mirum Pharmaceuticals调整后每股亏损为12美分，远好于分析师平均预期的33美分亏损，也大幅改善了去年同期52美分的亏损。公司营收同比增长64.1%，达到1.2779亿美元，同样超过了分析师预期的1.0817亿美元。尽管公司当季仍录得586万美元亏损，但整体业绩表现令人鼓舞。
值得注意的是，华尔街分析师对Mirum Pharmaceuticals保持乐观态度。目前，分析师对该公司股票的平均评级为"买入"，其中10个评级为"强烈买入"或"买入"。分析师给出的12个月目标价中位数为73.00美元，较其最新收盘价51.84美元高出约29%。这表明市场对公司未来发展前景持积极看法，可能进一步支撑股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.